Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 9/20 | 0.52 |
| ▸ | AURKA | O14965 | 8/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203017 | 0.88 | AURKB (0.55) | AURKBAURKASRCGSK3BMAPT | |
| SCHEMBL2203178 | 0.86 | AURKB (0.53) | AURKBAURKASRCGSK3BMAPT | |
| SCHEMBL2200635 | 0.84 | AURKB (0.61) | AURKBAURKASRCGSK3BMAPT | |
| SCHEMBL28570220 | 0.83 | BPTF (0.38) | AURKBAURKAMLKLMAPTTP53 | |
| SCHEMBL2205038 | 0.83 | AURKB (0.75) | AURKBAURKASRCGSK3BMAPT | |
| SCHEMBL2205873 | 0.82 | AURKB (0.63) | AURKBAURKASRCGSK3BMAPT | |
| SCHEMBL2206017 | 0.81 | AURKA (0.61) | AURKBAURKASRCGSK3BMLKL | |
| SCHEMBL2204620 | 0.81 | AURKA (0.51) | AURKBAURKASRCGSK3BMAPT | |
| SCHEMBL2204846 | 0.80 | AURKB (0.76) | AURKBAURKASRCGSK3BMAPT | |
| SCHEMBL2203480 | 0.79 | AURKB (0.59) | AURKBAURKASRCGSK3BAURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4210520-B2 | — | — | 2009-01-21 | — | — | JP | claimed |
| EP-1353916-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-09-20 | — | — | EP | claimed |
| EP-1702920-A1 | Pyrazole compounds useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2006-09-20 | — | — | EP | claimed |
| JP-2004517894-A | — | — | 2004-06-17 | — | — | JP | claimed |
| US-6664247-B2 | Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease. | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-16 | — | — | US | claimed |
| EP-1353916-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030036543-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-02-20 | — | — | US | claimed |
| WO-2002057259-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-07-25 | — | — | WO | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-06-16 | — | — | US | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| EP-1702920-B1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7982037-B2 | (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | AURKB 664/4885AURKA 1018/4885SRC 1484/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | AURKB 1003/4885AURKA 1514/4885SRC 1586/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | AURKB 398/4885AURKA 767/4885SRC 1229/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | AURKB 206/4885AURKA 698/4885SRC 1261/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | AURKB 1940/4885AURKA 1829/4885SRC 3197/4885 |
| US-20030036543-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKB 4/4885AURKA 2/4885SRC 419/4885 |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | AURKB 206/4885AURKA 698/4885SRC 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.